Skip to main content

Therapy Acceleration Program

Portfolio

Therapy Acceleration Program

Portfolio

Since 2017, four TAP-supported therapies have been approved by the U.S. Food and Drug Administration (FDA) or included in the National Comprehensive Cancer Network (NCCN) Guidelines:

Currently, there are over 20 active clinical studies with TAP-supported assets, including 6 registration-enabling clinical studies (4 in blood cancer & 2 beyond blood cancer).


TAP Portfolio Assets in Company Sponsored Trials - Blood Cancer Development

TAP Portfolio Assets in Company Sponsored Trials - Blood Cancer Development